Related Experiment Video
Updated: May 4, 2026
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
New perspectives in ovarian cancer treatment
Bernd C Schmid1, Martin K Oehler2
1Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, South Australia, Australia.
Abstract:
Ovarian cancer (OC) is increasingly understood as a heterogeneous disease comprising distinct subtypes of different origin that vary significantly with regard to molecular biology and clinical behaviour. Despite some limited progress in its treatment over the last decade, currently there are few therapeutic options and overall survival remains poor. Increasing knowledge about the molecular biology of ovarian cancer has led to the development of targeted therapies which promise to be more effective and to provide the basis for personalized treatment. The most successful strategies so far are employing anti-angiogenics (VEGF antibodies, tyrosine kinase inhibitors and angiopoietin antagonists) and polyadenosine diphosphate-ribose polymerase (PARP) inhibitors. Other approaches target aberrant OC signalling such as the PI3K/Akt/mTOR network, the epidermal growth factor receptor, the WEE1 tyrosine kinase and the folate receptor alpha. Immunotherapy is another promising new approach against ovarian cancer. In this area, immunotherapeutic modulation by administering autologous immune cells, such as dendritic cells (DCs), to stimulate antitumour host responses is of special interest. Finally, there is now growing evidence from clinical studies showing a survival advantage for intraperitoneal (IP) chemotherapy when compared to conventional intravenous treatment in the adjuvant setting. New strategies such as pressurized IP aerosol chemotherapy might further improve the efficacy of this approach.
Insights
Ovarian cancer (OC) is a complex disease with limited treatment options. Advances in targeted therapies, including anti-angiogenics and PARP inhibitors, alongside immunotherapy and intraperitoneal chemotherapy, offer new hope for improved patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Ovarian cancer (OC) is a heterogeneous disease with poor survival rates and limited therapeutic options.
- Recent advances in understanding OC's molecular biology have spurred the development of targeted therapies.
- Personalized treatment strategies are emerging due to increased molecular insights.
Purpose of the Study:
- To review current and emerging therapeutic strategies for ovarian cancer.
- To highlight the role of targeted therapies, immunotherapy, and novel drug delivery methods.
- To discuss the potential for improved patient outcomes through personalized medicine.
Main Methods:
- Review of recent clinical studies and molecular research in ovarian cancer.
- Analysis of targeted therapies including anti-angiogenics (e.g., VEGF antibodies) and PARP inhibitors.
- Exploration of immunotherapeutic approaches, such as dendritic cell (DC) therapy, and intraperitoneal (IP) chemotherapy.
Main Results:
- Anti-angiogenics and PARP inhibitors are currently the most successful targeted therapies.
- Targeting signaling pathways like PI3K/Akt/mTOR and receptors like folate receptor alpha shows promise.
- Intraperitoneal chemotherapy demonstrates a survival advantage over intravenous treatment in the adjuvant setting.
Conclusions:
- Targeted therapies, immunotherapy, and optimized drug delivery (e.g., IP chemotherapy) represent promising avenues for ovarian cancer treatment.
- Personalized medicine based on molecular subtypes holds potential for improving patient survival.
- Further research into novel strategies like pressurized IP aerosol chemotherapy is warranted.
Related Concept Videos
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistent Cancers